Condition: REM Sleep Behavior Disorder · Sponsor: Yale University
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.
This description comes directly from the study's public registry record.
Erika Renkl, BA · 475-254-9169 · erika.renkl@yale.edu
Kathy Gerich · katherine_gerich@URMC.rochester.edu
Always discuss trial participation with your own doctor first.
| Cedars Sinai Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| University of Colorado Anschutz | Aurora, Colorado, United States | Recruiting |
| Yale Medicine | North Haven, Connecticut, United States | Not Yet Recruiting |
| Parkinson's Disease & Movement Disorders Center of Boca Raton | Boca Raton, Florida, United States | Not Yet Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Not Yet Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Not Yet Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| Washington University | St Louis, Missouri, United States | Not Yet Recruiting |
| Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas | Las Vegas, Nevada, United States | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06996652